BRIEF—$200 million US IPO for Belgium's Ablynx

Belgium’s Ablynx has raised $200 million from an initial public offering for its new US business, which is listing on the Nasdaq.

Previously the company said it expected to raise $150 million.

The company has appointed Daniel Schneider as the general manager at the new subsidiary, where he will lead the commercialization of rare disease therapy caplacizumab in North America.

The biotech firm, which is listed on the Euronext in Brussels, has a proprietary Nanobody platform which it is using to develop treatments in a range of therapy areas.

The closing of the offering is expected to occur on 27 October.